Weight Loss Maintenance Data Could Be A Big Test For Viking Therapeutics Stock (VKTX)

• Viking Therapeutics completed a US$225 million convertible note offering and a US$275.0 million follow-on equity sale shortly after reporting past positive top line VK2735 maintenance data in obesity.
• The pairing of strong VK2735 weight maintenance results with fresh debt and equity raises gives Viking Therapeutics more funding flexibility to run longer, larger trials and expand its obesity pipeline without relying only on existing cash.
• This article examines how Viking Therapeutics' investment narrative shifts as VK2735's weight maintenance data supports less frequent dosing in obesity.

Scan how other obesity and metabolic stocks are positioned by running through our hand picked 35 healthcare AI stocks alongside Viking Therapeutics' fresh VK2735 data and new funding runway.

Viking Therapeutics Investment Narrative Recap

To own Viking Therapeutics, you effectively need to back VK2735 as a future obesity franchise and accept a period of heavy spending with no product revenue. The big near term swing factor is clean progress through large obesity trials and further clarity on oral VK2735, since delays or safety issues would hit that thesis directly.

The recent VK2735 maintenance data and the paired US$500 million capital raise give the business extra room to keep funding VANQUISH trials, oral studies and early amylin work while running at a loss. Execution risk remains high, but near term the key operational watchpoints are trial timelines, safety updates and how quickly oral and injectable programs move into later stages.

The follow on equity offering of US$275.0 million, alongside 7,857,143 new shares at US$35, is the most relevant announcement here. It interacts directly with the VK2735 data because it impacts how aggressively Viking Therapeutics can fund larger and longer obesity studies, commercial build out and manufacturing commitments while still relying on its balance sheet.

Fresh equity and the US$225 million convertible notes provide more flexibility but also add dilution and higher risk funding to a business that already reported a US$358.5 million loss in 2025 and has no revenue. For you, the trade off is simple. More cash supports execution on VK2735 and the wider metabolic pipeline; the main risk is that extended R&D and commercial spend stretch out without a clear path to product approvals.

What The VK2735 Forecasts Assume

Viking Therapeutics' narrative projects US$118.5 million revenue and US$12.9 million earnings by 2029. This implies a move from no sales today and an earnings increase of about US$372.5 million from the current loss of US$359.6 million.

Uncover how Viking Therapeutics' fair value indicates a 210% potential upside to its current price before that gap starts to close.

Exploring Other Perspectives

One alternate angle on Viking Therapeutics focuses on dilution risk. The most bullish analysts, who were pencilling in US$497.5 million of 2029 revenue and US$62.2 million of earnings before this news, assume future share issuance stays manageable. You can now ask whether a US$500 million mix of equity and convertibles shifts that story and prompts fresh forecasts.

Explore 3 other Viking Therapeutics fair value estimates, including one that suggests up to 217% upside from the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis and judgment.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• See our latest analysis for Viking Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Looking For More Investment Ideas Beyond Viking Therapeutics?

Once you have formed a view on Viking Therapeutics, it can help to line it up against other opportunities so you are not relying on a single obesity story. The Simply Wall St Screener lets you quickly filter the market by balance sheet quality, income focus or potential upside so you can build a watchlist that matches your own risk limits.

• If capital preservation is a priority, start with companies that score well on financial strength and cash backing by reviewing our list of solid balance sheet and fundamentals (26 results).
• If your focus is income, scan reliable payers with higher yields and stress test your options against our 7 dividend fortresses.
• If you are hunting for under the radar ideas with strong fundamentals, cast a wider net using the 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com